Morningstar

H. Lundbeck AS Ordinary Shares - Class B HLUN B

Morningstar Rating
Unlock
Stock XCSE Rating as of
DKK 45.08 +0.24 (0.54%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Lundbeck's Strategic Brands Help Offset Generic Erosion Amid Upcoming Patent Losses

Rachel Elfman

Lundbeck focuses on central nervous system drugs, including antidepressants, antipsychotics, and antiepileptic products. While incremental innovations and label expansions have helped Lundbeck earn excess returns over the last several years, this was before many of Lundbeck’s patents reached their expirations. Since then, generic entry has created a lot of competition and pricing pressure for the company.

Read Full Report

Price vs Fair Value

View History
HLUN B is trading at a 363% premium.
Price
DKK 45.08
Fair Value
DKK 95.20
Uncertainty
High
1-Star Price
DKK 64.46
5-Star Price
DKK 78.90
Economic Moat
Tmsg
Capital Allocation
Xtqpgft

Bulls Say, Bears Say

Bulls

Vyepti received FDA approval in 2020 and has already been launched in 24 markets globally.

Bears

Due to the complex nature of CNS disorders and the high frequency of placebo responses, which can confound trial results, the development process has been filled with obstacles.

Show More

Trading Information

Previous Close Price
DKK 44.84
Day Range
DKK 43.90–45.18
52-Week Range
DKK 31.62–48.50
Bid/Ask
DKK 45.00 / DKK 45.06
Market Cap
DKK 44.72 Bil
Volume/Avg
637,429 / 564,804

Key Statistics

Price/Earnings (Normalized)
9.01
Price/Sales
2.16
Dividend Yield (Trailing)
1.55%
Dividend Yield (Forward)
1.55%
Total Yield
1.65%

Company Profile

Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company’s portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson’s disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Stock Style Box
Mid Value
Total Number of Employees
5,800
Website
https://www.lundbeck.com

Competitors

Valuation

View More
Metric
HLUN B
ALNY
EXEL
Price/Earnings (Normalized)
 9.01152.1217.48
Price/Book Value
 1.93—3.59
Price/Sales
 2.1614.404.08
Price/Cash Flow
 8.5566.1016.68
Price/Earnings
HLUN B
ALNY
EXEL

Financial Strength

Metric
HLUN B
ALNY
EXEL
Quick Ratio
 1.322.784.05
Current Ratio
 1.883.014.27
Interest Coverage
 —−0.35—
Quick Ratio
HLUN B
ALNY
EXEL

Profitability

Metric
HLUN B
ALNY
EXEL
Return on Assets (Normalized)
 11.51%5.94%14.82%
Return on Equity (Normalized)
 19.52%—19.05%
Return on Invested Capital (Normalized)
 15.80%21.50%14.99%
Return on Assets
HLUN B
ALNY
EXEL

Drug Manufacturers - Specialty & Generic Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Zoetis Inc Class A
ZTS
CywjzfhpfVpd$86.1 Bil
 Merck KGaA ADR
MKKGY
TcxrhlbqbWbvdxpt$74.3 Bil
 Haleon PLC ADR
HLN
ZshzxgvrtXynf$45.9 Bil
 Viatris Inc
VTRS
SfbwnzdgXstmd$13.8 Bil
 Dr Reddy's Laboratories Ltd ADR
RDY
CztfzcgwtBwz$13.2 Bil
 Catalent Inc
CTLT
KrxyrpgdTrbmwj$11.0 Bil
 Prestige Consumer Healthcare Inc
PBH
SfqtbvctVhcckp$3.4 Bil
 Perrigo Co PLC
PRGO
WbptxjvzNjkp$3.4 Bil
 Green Thumb Industries Inc
GTBIF
YgbpsqwybSdt$2.4 Bil
 Curaleaf Holdings Inc
CURLF
PxqqvslfLbjt$2.2 Bil

Sponsor Center